April 14, 2021 PAO-04-22-R221-19
Will Downie, CEO of Vectura Group, discusses the company’s rebranding and entry into the CDMO space for device and drug development.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Vectura was established in 1997 to identify and develop opportunities in drug formulation and delivery. Vectura has evolved into a product development company that focuses on the development of pharmaceutical therapies for airways diseases.With our extensive range of technologies, capabilities, and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases worldwide.